Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQDN46)

Drug Name

PLN-74809 Drug Info

Synonyms

Bexotegrast; PLN-74809; 2376257-44-0; QCV154PFT4; Pln 74809; Bexotegras; (2S)-4-(2-Methoxyethyl-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid; Bexotegras [INN]; Butanoic acid, 4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(4-quinazolinylamino)-, (2S)-; Butanoic acid, 4-[(2-methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(4-quinazolinylamino)-, (2S)-; bexotegrast [INN]; UNII-QCV154PFT4; CHEMBL5095257; SCHEMBL21329445; GTPL12108; US10793564, Compound 5; BDBM465216; GLXC-26826; (S)-4-((2-Methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; PLN 74809 [WHO-DD]; PLN74809; US10793564, Compound 55; BDBM50594476; AKOS040757614; MS-29155; HY-137561; CS-0140405; (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]
Primary sclerosing cholangitis	DB96.2	Phase 2	[2]

Cross-matching ID

PubChem CID: 135390719
TTD Drug ID: DMQDN46

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-V/beta-6 (ITGAV/B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
STX-100	DMR9COG	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
CWHM-12	DM8YUJT	Hepatic fibrosis	DB93.0	Preclinical	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5/beta-1 (ITGA5/B1)	TTHWZMR	ITAV_HUMAN-ITB1_HUMAN	Inhibitor	[3]
Integrin alpha-V/beta-6 (ITGAV/B6)	TTIQSVM	ITAV_HUMAN-ITB6_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05621252) A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04480840) A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). U.S.National Institutes of Health.
3	Dual inhibition of alpha(v)beta(6) and alpha(v)beta(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265.
4	Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896.
5	Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.